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ABSTRACT 
Cathepsin B like cysteine proteases representing a major component of the lysosomal proteolytic repertoire plays an important role in 
intracellular protein degradation. Comparative models of cathepsin B (CatB) protein of six different Leishmania strains were developed using 
MODELLER. The modeled three-dimensional (3-D) structure has the correct stereochemistry as gauged from the Ramachandran plot and good 3-
D structure compatibility as assessed by PROCHECK and the DOPE score (DS2.1, Accelrys). The modeled proteins were energy minimized and 
validated using standard dynamic cascade protocol (DS 2.1). Seven different disulfide bonding sites are predicted in CatB protein of Leishmania. 
Two domains were identified and different motifs are present in catB protein of Leishmania like aspargine glycosylation site, protein kinase 
phosphorylation site, Protein kinase C activation site, N-myristoylation site. Considering that cathepsin B is essential for survival of Leishmania, 
including for virulence to the mammalian host, it may be viewed as an attractive drug target. 
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INTRODUCTION 
Leishmaniasis, a vector-borne disease that is caused by 
obligate intra-macrophage protozoa (Leishmania) is 
endemic in large areas of the tropics, subtropics and the 
Mediterranean basin. This disease is characterized by both 
diversity and complexity1-3. Form World Health Organization 
(WHO) estimated the number of persons at risk to be around 
350 million and the number of new cases to be 2,357,000 per 
year. It is caused by more than twenty leishmanial species 
and is transmitted to human’s by-30 different species of 
phebotomine sand-flies4-6.  
In muco-cutaneous leishmaniasis, patients suffer from 
progressively destructive ulcerations of the mucosa, 
extending from the nose and mouth to the pharynx and 
larynx. These lesions are not self-healing and are usually 
seen months or years after a first episode of cutaneous 
leishmaniasis, when the macrophages of the naso-
oropharygeal mucosa become colonized, Leishmania 
braziliensis is responsible for most cases of muco-cutaneous 
leishmaniasis7-9. 
Current drug treatment for Leishmania is either lacking or 
unsatisfactory and new drugs for clinical use are too 
expensive to develop through classical empirical screening 
methods. Research is now being directed toward identifying 
key differences between the metanolism of host and parasite 
as target for drug development. Current treatments for 
leishmaniasis have several side effects. The demand for 
chemotherapeutic agents for the treatment of kala azar is 
desperate. Those needing treatment are mainly in 
impoverished rural and rural and urban communities with 
poor housing and limited access to medical attention. 
Approved chemotherapies that are available were developed 
in the first half of the last century (Suramine, Pentamidine, 
Arsenicals and Antimonial); some would fail today’s more 
stringent standards for drug safety. Given the initial success 
of a largely empirical approach, progress in drug 
development in recent years has been diseases by parasite 
Leishmania. In view of the economies of the Third World 
countries suffering most from these diseases, such drugs will 
have to be cheap and simple to administer10-12. 
MATERIALS AND METHODS 
The software and tool, which are used for searching journal, 
protein analysis, for knowing sequence of protein and also 
comparing the sequence, modeling of protein comparing 3D 
structure of protein, active site finding and molecular 
docking and ligand design, ADMET predication are the 
following: - 
For Protein Modelling: MODELLER 9V5, Swiss Models, 
Discovery Studio (Accelrys) 
For Docking: GOLD 2.1, AutoDock 4.0, Ligand fit (Accelrys 
DS 2.0) 
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RESULTS AND DISCUSSION 
BioEdit is a fully integrated sequence/alignment editor, 
Performs translation, Phylogenetic analysis Clustal w 
alignments, ABI trace analysis, RNR comparative analysis 
and BLAST searches.  
Amino Acid Composition: Protein: gi|190335775|gb| 
ACE74540.1|enolase [Leishmania donovani] 
Length = 429 amino acids 
Molecular weight=46062.21 Daltons 
 
Table 1: Amino Acid Composition 
Amino Acid  Number Mol% 
Ala A 54 12.59 
Cys C 11 2.56 
Asp D 20 4.66 
Glu E 35 8.16 
Phe F 11 2.56 
Gly G 38 8.86 
His H 6 1.40 
He I 27 6.29 
Lys K 29 6.76 
Leu L 31 7.23 
Met  M 14 3.26 
Asn N 17 3.96 
Pro P 19 4.43 
Gln Q 9 2.10 
Arg R 17 3.96 
Ser S 24 5.59 
Thr T 22 5.13 
Val V 28 6.53 
Trp W 3 0.70 
Tyr Y 14 3.26 
  
Table 2: Dock Score of Ligand Molecules of Different Class of Enolase Inhibitors 
S.NO. Compounds Name NO. of 
poses 
Active Sites Dock Score By 
Discovery Studio 
H- Bonding with amino 
acids 
13. CID_10496295 
Cocaethylene 
10 SITE 2 54.39 CYS,LYS,GLU 
14. CID_10893799 
Nitrendiplne 
10 SITE 2 53.94 GLU,LYS 
15. CIDN_7130196 
Sidnocarb 
10 SITE 2 53.38 LYS,GLU,ASN 
16. CID_10569396 
Sulindac Sulfide 
10 SITE 2 52.52 ASN,LYS,ARG 
17. CID_6437875 
FK 409 
10 SITE 2 51.82 CYS,LYS,ASN 
18. CID_688267 
Captopril 
10 SITE 2 51.58 ARG,LYS.CYS 
19. CID_10775595 
Stavudine 
10 SITE 2 51.43 GLU,ASN,LYS 
20. CID_11781231 
Galantamine 
10 SITE 2 51.28 LYS,GLU 
21. CID_456314 
Didanosine 
10 SITE 2 50.94 GLU,ASN 
22. CID_677668 
STK361792 
10 SITE 2 50.73 ASN,GLU,LYS 
23. CID_10627235 
Isbesartan 
10 SITE 2 50.58 LYS,ARG 
24. CID_10262057 
Ferulic Acid 
10 SITE 2 50.54 ASN,GLU 
25. CID_11452157 
Naftopidil 
10 SITE 2 50.41 LYS,ASN,GLU 
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QSAR Descriptors 
A DESCRIPTORS is a molecular property that QSAR an calculate. It provides a wide variety of DESCRIPTORS that we can use in 
determining new QSAR relationships. Some DESCRIPTORS are given below. 
Parameters LIG .1 LIG .2 LIG .3 LIG .4 LIG .5 LIG .6 LIG .7 LIG .8 
Molecular mass 317.42 324.46 360.4 261 136.22 211.25 338.78 262.31 
Molecular surface area 311.70 273.65 343.72 197.18 175.26 213.06 282.81 235.11 
Molecular volume 249.12 211.75 270.93 152.55 110.08 149.85 228.29 174.85 
Ellipoidal volume 1472.0 978.81 643.22 284.27 302.09 343.34 892.95 608.32 
Rotatable bonds 6 3 6 3 3 2 2 2 
No. of atoms 46 35 46 18 22 28 33 31 
No. of hetroatoms 5 9 8 12 2 6 8 8 
ADME weight 317.4 324.46 360.4 261 136.22 211.25 338.78 262.31 
ADME h-bond accepter 5 5 6 10 0 4 4 5 
ADME h- bond 0 2 1 0 2 2 3 5 
 
Donar         
ADME log P 2.2678 -0.6498 0.5848 -2.015 0 -0.3252 2.1436 -1.0375 
ADME rotatable  bonds 6 3 6 3 3 2 2 2 
VAMP electronic energy 30999.8 24588.7 36811.9 13554.9 5960.0 16327.9 27063.5 21267.1 
VAMP nuclear energy 26889.6 20809.5 31898.6 9667.98 4374.6 13414.6 22857.3 17711 
VAMP surface area 362.95 311.49 384.81 250.55 207.16 231.65 309.37 263.49 
VAMP heat of formation -138.18 -121.16 -123.73 -437.78 -434.2 -85.514 -78395 -188.66 
VAMP ionization potential 9.6670 9.9017 9.0334 -3.727 15.281 9.1976 10.098 8.8546 
VAMP symmetry point group C1 C1 C1 C1 C1 C1 C1 C1 
 
CONCLUSION 
Ligand protein interaction study of various categories of 
inhibitors like Anti-HIV Agents, Monoamine Oxidase 
Inhibitors, Antimetabolites, Insecticides, Anti-Hypertensive 
Agents, Diuretics derivatives and available antileishmanial 
drugs) and enolase of Leishmania donovani were carried out 
in GOLD, ligand-fit tool of Discovery Studio. This study has 
shown that some inhibitors have greatest binding affinities 
to the active site enolase protein and have shown formation 
fo favourable hydrogen bonds, hence it is predicted from this 
stydy that these novel compounds may be acting as potent 
inhibitors for Leishmania enolase. 
The drugs like Phenelzine, Parzyline, Thiouridine, 
Nitrendipine, ehlorthalidone and Phoxim which shown good 
dock score from Discovery Studio as well as from GOLD were 
further assessed by pre ADMET (online tool) which shown 
very good HIA (human intestinal absorption) value, and 
negative carcinogenicity. After that QSAR studies were 
performed by TSAR software from that so many descriptors 
were obtained that could be used in determining new QSAR 
relationships. 
These compounds may be used further for synthesis, their 
wet lab activity against enolase, animal model study and 
clinical trials and then can be implicated for the treatment of 
leishmaniasis. Those models are considered to be used in 
designing new leads for hopefully more active compounds. 
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